<DOC>
	<DOCNO>NCT01611480</DOCNO>
	<brief_summary>The aim evaluate efficacy safety three different dose regimen Limtop study involve 96 patient actinic keratosis head face .</brief_summary>
	<brief_title>Efficacy Safety New Topical Formulation With Imiquimod ( Limtop ) Applied 1 , 3 7 Times Weekly During 2 x 2 Weeks Treatment Actinic Keratosis Head</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Written inform consent form ( ICF ) sign date patient prior studyrelated activity 2 . Male female patient age 18 old 3 . Have total 520 clinically confirm , palpable visible ( grade I II accord modify Olsen score ) nonhyperkeratotic , nonhypertrophic AK lesion locate within contiguous 25 100 cm² area bald scalp face 4 . Any skin type race , provide skin pigmentation allow discernment erythema 5 . Willingness actively participate study comply study procedure define study protocol 6 . High probability good compliance orderly completion study 7 . Negative urine pregnancy test ( female subject childbearing potential ) 1 . Evidence clinically significant , unstable cardiovascular immunosuppressive , hematologic , hepatic , neurologic , renal , endocrine , collagenvascular , gastrointestinal abnormality disease 2 . Diagnosed autoimmune disease anaemia 3 . Any dermatological disease condition treatment surround area may exacerbate treatment imiquimod cause difficulty examination ( e.g . rosacea , psoriasis , atopic dermatitis , eczema ) 4 . Any significant finding ( e.g . tattoo ) potential application site area may impair examination treatment surround area 5 . Confirmed squamous cell basal cell carcinoma anywhere head past 3 month 6 . Share household person participate concurrent clinical study imiquimod treat imiquimod 5 % topical cream 7 . Active chemical dependency alcoholism , assess investigator 8 . Patients unwilling stay sun wear protective clothing take appropriate measure cover treatment area study 9 . Previous treatment imiquimod AK predetermine treatment area within past 3 month 10 . Treatment COX2 inhibitor 14 day prior randomization 11 . Currently use use treatment area overthecounter retinol product , corticosteroid , cryosurgery , curettage , 5fluorouracil , topical actinic keratosis treatment 28 day prior randomization 12 . Subjects experience unsuccessful outcome previous imiquimod therapy . 13 . Known allergy sensitivity imiquimod excipients ( butyl lactate , isopropyl myristate , propylene glycol , butylate hydroxy anisole ) IMP 14 . Premenopausal ( last menstruation ≤ 1 year prior screen ) sexually active woman : pregnant nursing , surgically sterile , child bear potential practicing acceptable method birth control , plan continue practice acceptable method birth control throughout trial ( acceptable method include intrauterine device ( IUD ) , oral , implantable injectable contraceptive , diaphragm cervical cap intravaginal spermicide , condom intravaginal spermicide vasectomise partner ) 15 . Participation another clinical trial investigational drug device previous 4 week Baseline 16 . Receiving systemic cancer chemotherapy , psoralen plus UVA therapy , UVB therapy , laser abrasion , dermabrasion , glycolic acid , chemical peel 6 month prior study entry . 17 . Currently use use systemic steroid 2 month prior study except inhaled corticosteroid ( &lt; 1200 microgram/day beclomethasone , &lt; 600 microgram/day fluticasone ) 18 . Known infectious disease ( e.g . HIV , hepatitis ) 19 . Psychiatric condition might limit participation study and/or lead assumption ability completely understand consequence consent miss 20 . The Patient institutionalize virtue order issue either judicial administrative authority 21 . Employee study site Sponsor 's company 22 . Any disease circumstance account subject participate study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>